Catalyst Financial Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Catalyst Financial Partners's REGN Position: Q2 2026 in Review
Catalyst Financial Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 23% in Q2 2026, selling an estimated $72.8K and leaving 355 shares worth $221K. The position accounts for 0.02% of the portfolio, ranked #380.
Catalyst Financial Partners first reported a position in REGN in Q3 2023 and has held it in 9 quarters since. The position peaked at $357K in Q1 2026. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Catalyst Financial Partners held 355 shares of Regeneron Pharmaceuticals worth $221K as of Q2 2026.
- Catalyst Financial Partners sold 107 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $72.8K.
- Regeneron Pharmaceuticals made up 0.02% of Catalyst Financial Partners's portfolio in Q2 2026, its #380 holding.
- Catalyst Financial Partners first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
- Catalyst Financial Partners's Regeneron Pharmaceuticals position peaked at $357K in Q1 2026.
- 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Catalyst Financial Partners's 13F filing for Q2 2026, filed 30 Jul 2026.